The United States Food and Drug Administration (USFDA) has concluded a current Good Manufacturing Practices (cGMP) inspection at Emcure Pharmaceuticals’ formulations facility located at G.I.D.C., Sanand, Ahmedabad, Gujarat. The inspection was conducted from May 06, 2026 to May 15, 2026.
At the conclusion of the inspection, the company was issued a Form 483 with 7 observation(s). The observations are procedural in nature.
Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
